Change in shareholder structure: new majority owners are Ren Life Sciences and Juno Capital Partners, who acquired the stakes held by prior investors (including KfW and IBG-Fonds). SHS Capital and AMW Evolution remain invested. No investment amount or valuation disclosed. Company reported record revenue in fiscal year 2025.
About AMW GmbH
Specialist pharmaceutical company focused on biodegradable drug-delivery systems, developing and manufacturing implants that release drugs (e.g., goserelin, leuprorelin) for improved adherence and cost-efficient treatments.
Warngau, Germany
Read Company ProfileFrequently Asked Questions
What type of funding round did AMW GmbH raise?
AMW GmbH raised a unspecified round.
When did AMW GmbH raise its unspecified?
AMW GmbH raised its unspecified on 2026-03-05.
Who invested in AMW GmbH's unspecified?
The investors in AMW GmbH's unspecified are: Ren Life Sciences, Juno Capital Partners, SHS Capital, KfW, IBG-Fonds.
What type of investment was AMW GmbH's unspecified?
AMW GmbH's unspecified was a equity investment.
How will AMW GmbH use the funds from its unspecified?
AMW GmbH plans to use the funds for: support international growth, expand development, manufacturing and commercialization of biodegradable drug-delivery systems.